Welcome to our dedicated page for Alnylam Pharmaceuticals SEC filings (Ticker: ALNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical-stage biotech filings can feel like decoding a laboratory notebook. Alnylam Pharmaceuticals’ RNAi pipeline spans rare-disease trials, partnership milestones, and intricate cash-flow disclosures—details scattered across hundreds of pages. If you’ve searched for “Alnylam SEC filings explained simply” or wondered how to spot pivotal RNAi data buried in its 10-K, you’re not alone.
Stock Titan solves that problem in minutes. Our AI parses every Alnylam quarterly earnings report 10-Q filing, tags key metrics like cash runway, and delivers real-time alerts on Alnylam Form 4 insider transactions—so you never miss a chief scientist’s stock move. Need the Alnylam annual report 10-K simplified? We highlight pipeline progress, collaboration revenue, and patent cliffs. Curious about “Alnylam 8-K material events explained”? We translate FDA designations, partnership amendments, and trial readouts into plain English. From Alnylam executive stock transactions Form 4 to the proxy statement executive compensation tables, all documents stream directly from EDGAR with instant AI summaries.
Use cases investors rely on:
- Monitor Alnylam insider trading Form 4 transactions before material announcements
- Compare RNAi program spending across each Alnylam earnings report filing analysis
- Review Alnylam proxy statement executive compensation to gauge R&D incentives
- Track Alnylam quarterly earnings report 10-Q filing for clinical-trial cash needs
- Receive Alnylam Form 4 insider transactions real-time for sentiment signals
Understanding Alnylam SEC documents with AI means faster decisions based on the disclosures that actually move a biotech stock.
Dennis A. Ausiello, a director of Alnylam Pharmaceuticals, executed multiple equity transactions on 08/14/2025 under a Rule 10b5-1(c) trading plan adopted May 15, 2025. The Form 4 reports exercises of stock options (codes M(1)) for option blocks of 9,000; 5,153; 4,581; 5,228; 4,032; and 3,454 shares at exercise prices ranging from $72.01 to $189.87 per share, each creating corresponding shares of common stock. The filing also shows open-market sales (codes S(1)) of multiple share blocks at weighted-average prices reported in ranges between $430.39 and $443.10 per share. After the reported transactions, the reporting person’s beneficial ownership counts are shown on individual lines (for example, 9,911; 15,064; 19,645; 24,873; 28,905; 32,359; then decreasing after sales to 911). Additionally, 3,500 shares are reported as indirectly owned by a trust for which the reporting person's spouse is trustee. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Ausiello on 08/15/2025.
Alnylam Pharmaceuticals (ALNY) reported a proposed sale under Rule 144 of 31,448 common shares valued at $13,635,538.00 based on the filing. The shares were acquired and are to be sold on 08/14/2025 through UBS Financial Services, Inc. via the exercise of stock options and paid in cash. The filing lists 131,079,015 shares outstanding for the class. The filer reports no shares sold in the past three months. The notice includes the signer’s representation that they are unaware of any undisclosed material adverse information about the issuer.
Alnylam Pharmaceuticals announced significant organizational changes with the combination of its Research and Early Development function and Development function into a single R&D organization. Key leadership appointments include:
- Dr. Pushkal Garg promoted to Executive VP, Chief Research and Development Officer with new compensation package: - Base salary: $825,000 - Annual incentive target: 65% of base salary - Long-term equity incentives to be determined
- Dr. Kevin Fitzgerald (Executive VP, Chief Scientific Officer) receives expanded responsibilities for external innovation with: - Increased annual incentive target to 60% of base salary - One-time restricted stock unit grant valued at $2.5M, vesting over 3 years
This strategic reorganization aims to streamline R&D operations and strengthen the company's innovation capabilities. The changes were approved by the People, Culture and Compensation Committee on June 12, 2025, with formal announcement made on June 18, 2025.
FAQ
What is the current stock price of Alnylam Pharmaceuticals (ALNY)?
What is the market cap of Alnylam Pharmaceuticals (ALNY)?
